2F5 antibody

Last updated

2F5 is a broadly neutralizing human monoclonal antibody (mAb) that has been shown to bind to and neutralize HIV-1 in vitro, making it a potential candidate for use in vaccine synthesis. [1] [2] 2F5 recognizes an epitope in the membrane-proximal external region (MPER) of HIV-1 gp41. 2F5 then binds to this epitope and its constant region interacts with the viral lipid membrane, which neutralizes the virus. [3]

Contents

Background

Human immunodeficiency virus type 1 (HIV-1) is the most common strain of HIV. It contains three structural genes and six regulatory genes. One of the structural genes is env , which codes for the surface proteins gp120 and gp41. Gp41, whose gene is the target for 2F5, is a transmembrane protein that associates with gp120 to bind the virus to CD4 and a chemokine co-receptor on the target cell and infect it. [4] 2F5 binds to the variable regions of env and neutralizes the virus before it infects target cells. [5]

Epitope

2F5 recognizes a core specific epitope, ELDKWAS, the amino acid sequence from positions 662 to 668 of env gp41. Mutations at each of these amino acid positions of the epitope showed a decrease in or loss of 2F5 binding affinity. [6] Further studies have expanded the ideal epitope beyond ELDKWAS and revealed that the extended linear epitope NEQELLELDKWASLWN [7] increased 2F5 affinity greatly. [8] The 3D structure of HIV-1 is believed to change throughout phases of the virus; 2F5 has highest binding affinity for its beginning and intermediate structures, and the least affinity for its late postfusion structure. [9] The region DKW of the core epitope must be in a β-turn conformation and have the correct side-chain positions for 2F5 to bind and neutralize. [10]

Mechanism

Research has suggested that a two-step process is necessary for 2F5 binding and neutralizing: recognition of the epitope on gp41 and a hydrophobic interaction with the lipid membrane of the virus by the 2F5 CDR H3 loop. [3] [11] The structure of the antibody is such that it readily binds to a membrane-proximal epitope, unbothered by steric hindrance. [9] It prevents infection by tightly binding to conserved structural regions and blocks membrane fusion by the HIV virus. [10] 2F5 may also be able to activate the complement system and ADCC to kill infected cells. [12]

Vaccine implications

2F5 is not the only HIV-1-neutralizing antibody found; however, it is the broadest and prevents viral infection when transferred passively to macaques infected with chimeric simian-humans immunodeficiency virus (SHIV), making it a focus of research on development of an HIV-1 vaccine. [10] [12] [13]

A major goal recently in HIV-1 vaccinations is eliciting the broadly neutralizing antibodies before the virus is actually established, since the virus integrates itself into the host's DNA. [10] Vaccine trials have been largely unsuccessful in eliciting a response using mimics of the env region, potentially because of its high genetic variability. [14]

The ELDKWAS sequence is conserved in 72% of HIV-1 isolates, [1] which makes it a potentially good candidate for vaccination targets. When creating a vaccine, the isotype appears to matter: compared to IgG, the IgA isotype bound the epitope with higher affinity, blocked HIV transmission to target cells, and inhibited endocytosis of HIV-1 by dendritic cells, though it did have lower ADCC activity than IgG. [15] [16] Studies in thermodynamics have further supported this: IgG has a much higher binding affinity than just the Fab region of the antibody, suggesting the constant region is important to neutralization. [17] This also indicates, as Fab is much smaller than IgG, that steric hindrance is not a problem for 2F5 and in fact may increase binding affinity. [9] Besides the conformation of the linear epitope, 2F5-like responses to vaccine are complicated by the fact that antibody recognition of the epitope may also be dependent on interactions with other areas of the env region, accessibility, or interactions with membrane lipids on target cells. [10]

See also

Related Research Articles

<span class="mw-page-title-main">HIV vaccine development</span> In-progress vaccinations that may prevent or treat HIV infections

An HIV vaccine is a potential vaccine that could be either a preventive vaccine or a therapeutic vaccine, which means it would either protect individuals from being infected with HIV or treat HIV-infected individuals.

<i>Feline immunodeficiency virus</i> Species of virus

Feline immunodeficiency virus (FIV) is a Lentivirus that affects cats worldwide, with 2.5% to 4.4% of felines being infected.

<i>Measles morbillivirus</i> Species of virus

Measles morbillivirus(MeV), also called measles virus (MV), is a single-stranded, negative-sense, enveloped, non-segmented RNA virus of the genus Morbillivirus within the family Paramyxoviridae. It is the cause of measles. Humans are the natural hosts of the virus; no animal reservoirs are known to exist.

<span class="mw-page-title-main">Rabies virus</span> Species of virus

Rabies virus, scientific name Rabies lyssavirus, is a neurotropic virus that causes rabies in animals, including humans. Rabies transmission can occur through the saliva of animals and less commonly through contact with human saliva. Rabies lyssavirus, like many rhabdoviruses, has an extremely wide host range. In the wild it has been found infecting many mammalian species, while in the laboratory it has been found that birds can be infected, as well as cell cultures from mammals, birds, reptiles and insects. Rabies is reported in more than 150 countries and on all continents except Antarctica. The main burden of disease is reported in Asia and Africa, but some cases have been reported also in Europe in the past 10 years, especially in returning travellers.

<span class="mw-page-title-main">Epitope mapping</span> Identifying the binding site of an antibody on its target antigen

In immunology, epitope mapping is the process of experimentally identifying the binding site, or epitope, of an antibody on its target antigen. Identification and characterization of antibody binding sites aid in the discovery and development of new therapeutics, vaccines, and diagnostics. Epitope characterization can also help elucidate the binding mechanism of an antibody and can strengthen intellectual property (patent) protection. Experimental epitope mapping data can be incorporated into robust algorithms to facilitate in silico prediction of B-cell epitopes based on sequence and/or structural data.

The genome and proteins of HIV (human immunodeficiency virus) have been the subject of extensive research since the discovery of the virus in 1983. "In the search for the causative agent, it was initially believed that the virus was a form of the Human T-cell leukemia virus (HTLV), which was known at the time to affect the human immune system and cause certain leukemias. However, researchers at the Pasteur Institute in Paris isolated a previously unknown and genetically distinct retrovirus in patients with AIDS which was later named HIV." Each virion comprises a viral envelope and associated matrix enclosing a capsid, which itself encloses two copies of the single-stranded RNA genome and several enzymes. The discovery of the virus itself occurred two years following the report of the first major cases of AIDS-associated illnesses.

<span class="mw-page-title-main">Envelope glycoprotein GP120</span> Glycoprotein exposed on the surface of the HIV virus

Envelope glycoprotein GP120 is a glycoprotein exposed on the surface of the HIV envelope. It was discovered by Professors Tun-Hou Lee and Myron "Max" Essex of the Harvard School of Public Health in 1984. The 120 in its name comes from its molecular weight of 120 kDa. Gp120 is essential for virus entry into cells as it plays a vital role in attachment to specific cell surface receptors. These receptors are DC-SIGN, Heparan Sulfate Proteoglycan and a specific interaction with the CD4 receptor, particularly on helper T-cells. Binding to CD4 induces the start of a cascade of conformational changes in gp120 and gp41 that lead to the fusion of the viral membrane with the host cell membrane. Binding to CD4 is mainly electrostatic although there are van der Waals interactions and hydrogen bonds.

<span class="mw-page-title-main">Gp41</span> Subunit of the envelope protein complex of retroviruses

Gp41 also known as glycoprotein 41 is a subunit of the envelope protein complex of retroviruses, including human immunodeficiency virus (HIV). Gp41 is a transmembrane protein that contains several sites within its ectodomain that are required for infection of host cells. As a result of its importance in host cell infection, it has also received much attention as a potential target for HIV vaccines.

Antigenic variation or antigenic alteration refers to the mechanism by which an infectious agent such as a protozoan, bacterium or virus alters the proteins or carbohydrates on its surface and thus avoids a host immune response, making it one of the mechanisms of antigenic escape. It is related to phase variation. Antigenic variation not only enables the pathogen to avoid the immune response in its current host, but also allows re-infection of previously infected hosts. Immunity to re-infection is based on recognition of the antigens carried by the pathogen, which are "remembered" by the acquired immune response. If the pathogen's dominant antigen can be altered, the pathogen can then evade the host's acquired immune system. Antigenic variation can occur by altering a variety of surface molecules including proteins and carbohydrates. Antigenic variation can result from gene conversion, site-specific DNA inversions, hypermutation, or recombination of sequence cassettes. The result is that even a clonal population of pathogens expresses a heterogeneous phenotype. Many of the proteins known to show antigenic or phase variation are related to virulence.

Entry inhibitors, also known as fusion inhibitors, are a class of antiviral drugs that prevent a virus from entering a cell, for example, by blocking a receptor. Entry inhibitors are used to treat conditions such as HIV and hepatitis D.

Env is a viral gene that encodes the protein forming the viral envelope. The expression of the env gene enables retroviruses to target and attach to specific cell types, and to infiltrate the target cell membrane.

<span class="mw-page-title-main">Antibody-dependent enhancement</span> Antibodies rarely making an infection worse instead of better

Antibody-dependent enhancement (ADE), sometimes less precisely called immune enhancement or disease enhancement, is a phenomenon in which binding of a virus to suboptimal antibodies enhances its entry into host cells, followed by its replication. The suboptimal antibodies can result from natural infection or from vaccination. ADE may cause enhanced respiratory disease, but is not limited to respiratory disease. It has been observed in HIV, RSV virus and Dengue virus and is monitored for in vaccine development.

CD4 immunoadhesin is a recombinant fusion protein consisting of a combination of CD4 and the fragment crystallizable region, similarly known as immunoglobulin. It belongs to the antibody (Ig) gene family. CD4 is a surface receptor for human immunodeficiency virus (HIV). The CD4 immunoadhesin molecular fusion allow the protein to possess key functions from each independent subunit. The CD4 specific properties include the gp120-binding and HIV-blocking capabilities. Properties specific to immunoglobulin are the long plasma half-life and Fc receptor binding. The properties of the protein means that it has potential to be used in AIDS therapy as of 2017. Specifically, CD4 immunoadhesin plays a role in antibody-dependent cell-mediated cytotoxicity (ADCC) towards HIV-infected cells. While natural anti-gp120 antibodies exhibit a response towards uninfected CD4-expressing cells that have a soluble gp120 bound to the CD4 on the cell surface, CD4 immunoadhesin, however, will not exhibit a response. One of the most relevant of these possibilities is its ability to cross the placenta.

A cryptotope is an antigenic site or epitope hidden in a protein or virion by surface subunits. Cryptotopes are antigenically active only after the dissociation of protein aggregates and virions Some infectious pathogens are known to escape immunological targeting by B-cells by masking antigen-binding sites as cryptotopes. A cryptotope can also be referred to as a cryptic epitope. Cryptotopes are becoming important for HIV vaccine research as a number of studies have shown that cryptic epitopes can be revealed or exposed when HIV gp120 binds to CD4.

<span class="mw-page-title-main">Vpu protein</span>

Vpu is an accessory protein that in HIV is encoded by the vpu gene. Vpu stands for "Viral Protein U". The Vpu protein acts in the degradation of CD4 in the endoplasmic reticulum and in the enhancement of virion release from the plasma membrane of infected cells. Vpu induces the degradation of the CD4 viral receptor and therefore participates in the general downregulation of CD4 expression during the course of HIV infection. Vpu-mediated CD4 degradation is thought to prevent CD4-Env binding in the endoplasmic reticulum to facilitate proper Env assembly into virions. It is found in the membranes of infected cells, but not the virus particles themselves.

A neutralizing antibody (NAb) is an antibody that defends a cell from a pathogen or infectious particle by neutralizing any effect it has biologically. Neutralization renders the particle no longer infectious or pathogenic. Neutralizing antibodies are part of the humoral response of the adaptive immune system against viruses, intracellular bacteria and microbial toxin. By binding specifically to surface structures (antigen) on an infectious particle, neutralizing antibodies prevent the particle from interacting with its host cells it might infect and destroy.

Broadly neutralizing HIV-1 antibodies (bNAbs) are neutralizing antibodies which neutralize multiple HIV-1 viral strains. bNAbs are unique in that they target conserved epitopes of the virus, meaning the virus may mutate, but the targeted epitopes will still exist. In contrast, non-bNAbs are specific for individual viral strains with unique epitopes. The discovery of bNAbs has led to an important area of research, namely, discovery of a vaccine, not only limited to HIV, but also other rapidly mutating viruses like influenza.

<span class="mw-page-title-main">Susan Zolla-Pazner</span> American research scientist

Susan Zolla-Pazner is an American research scientist who is a Professor of Medicine in the Division of Infectious Diseases and the Department of Microbiology at Mount Sinai School of Medicine and a guest investigator in the Laboratory of Molecular Immunology at The Rockefeller University, both in New York City. Zolla-Pazner's work has focused on how the immune system responds to the human immunodeficiency virus (HIV) and, in particular, how antibodies against the viral envelope develop in the course of infection.

Intrastructural help (ISH) is where T and B cells cooperate to help or suppress an immune response gene. ISH has proven effective for the treatment of influenza, rabies related lyssavirus, hepatitis B, and the HIV virus. This process was used in 1979 to observe that T cells specific to the influenza virus could promote the stimulation of hemagglutinin specific B cells and elicit an effective humoral immune response. It was later applied to the lyssavirus and was shown to protect raccoons from lethal challenge. The ISH principle is especially beneficial because relatively invariable structural antigens can be used for the priming of T-cells to induce humoral immune response against variable surface antigens. Thus, the approach has also transferred well for the treatment of hepatitis B and HIV.

Catherine Blish is a translational immunologist and professor at Stanford University. Her lab works on clinical immunology and focuses primarily on the role of the innate immune system in fighting infectious diseases like HIV, dengue fever, and influenza. Her immune cell biology work characterizes the biology and action of Natural Killer (NK) cells and macrophages.

References

  1. 1 2 Muster, T.; Steindl, F.; Purtscher, M.; Trkola, A.; Klima, A.; Himmler, G.; Rüker, F.; Katinger, H. (1993-11-01). "A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1". Journal of Virology. 67 (11): 6642–6647. doi:10.1128/JVI.67.11.6642-6647.1993. ISSN   0022-538X. PMC   238102 . PMID   7692082.
  2. ↑ Shen, Xiaoying; Parks, Robert J.; Montefiori, David C.; Kirchherr, Jennifer L.; Keele, Brandon F.; Decker, Julie M.; Blattner, William A.; Gao, Feng; Weinhold, Kent J. (2009-04-15). "In Vivo gp41 Antibodies Targeting the 2F5 Monoclonal Antibody Epitope Mediate Human Immunodeficiency Virus Type 1 Neutralization Breadth". Journal of Virology. 83 (8): 3617–3625. doi:10.1128/JVI.02631-08. ISSN   0022-538X. PMC   2663270 . PMID   19193787.
  3. 1 2 Ofek, Gilad; McKee, Krisha; Yang, Yongping; Yang, Zhi-Yong; Skinner, Jeff; Guenaga, F. Javier; Wyatt, Richard; Zwick, Michael B.; Nabel, Gary J. (2010-03-15). "Relationship between Antibody 2F5 Neutralization of HIV-1 and Hydrophobicity of Its Heavy Chain Third Complementarity-Determining Region". Journal of Virology. 84 (6): 2955–2962. doi:10.1128/JVI.02257-09. ISSN   0022-538X. PMC   2826063 . PMID   20042512.
  4. ↑ Judith A. Owen; Jenni Punt; Sharon A. Stranford; Patricia P. Jones; Janis Kuby (2013-01-01). Kuby Immunology. W.H. Freeman. pp. A–1, 612. ISBN   978-1-4292-1919-8. OCLC   820117219.
  5. ↑ Jaworski, Juan Pablo; Vendrell, Alejandrina; Chiavenna, Sebastián Matias (2017-01-11). "Neutralizing Monoclonal Antibodies to Fight HIV-1: On the Threshold of Success". Frontiers in Immunology. 7: 661. doi: 10.3389/fimmu.2016.00661 . ISSN   1664-3224. PMC   5225137 . PMID   28123384.
  6. ↑ Yang, Guang; Holl, T. Matt; Liu, Yang; Li, Yi; Lu, Xiaozhi; Nicely, Nathan I.; Kepler, Thomas B.; Alam, S. Munir; Liao, Hua-Xin (2013-02-11). "Identification of autoantigens recognized by the 2F5 and 4E10 broadly neutralizing HIV-1 antibodies". The Journal of Experimental Medicine. 210 (2): 241–256. doi:10.1084/jem.20121977. ISSN   0022-1007. PMC   3570098 . PMID   23359068.
  7. ↑ Serrano, Soraya; Araujo, Aitziber; Apellániz, Beatriz; Bryson, Steve; Carravilla, Pablo; Arada, Igor de la; Huarte, Nerea; Rujas, Edurne; Pai, Emil F. (2014-03-07). "Structure and Immunogenicity of a Peptide Vaccine, Including the Complete HIV-1 gp41 2F5 Epitope IMPLICATIONS FOR ANTIBODY RECOGNITION MECHANISM AND IMMUNOGEN DESIGN". Journal of Biological Chemistry. 289 (10): 6565–6580. doi: 10.1074/jbc.M113.527747 . ISSN   0021-9258. PMC   3945320 . PMID   24429284.
  8. ↑ Parker, Carol E.; Deterding, Leesa J.; Hager-Braun, Christine; Binley, James M.; Schülke, Norbert; Katinger, Hermann; Moore, John P.; Tomer, Kenneth B. (2001-11-15). "Fine Definition of the Epitope on the gp41 Glycoprotein of Human Immunodeficiency Virus Type 1 for the Neutralizing Monoclonal Antibody 2F5". Journal of Virology. 75 (22): 10906–10911. doi:10.1128/JVI.75.22.10906-10911.2001. ISSN   0022-538X. PMC   114670 . PMID   11602730.
  9. 1 2 3 Ofek, Gilad; Tang, Min; Sambor, Anna; Katinger, Hermann; Mascola, John R.; Wyatt, Richard; Kwong, Peter D. (2004-10-01). "Structure and Mechanistic Analysis of the Anti-Human Immunodeficiency Virus Type 1 Antibody 2F5 in Complex with Its gp41 Epitope". Journal of Virology. 78 (19): 10724–10737. doi:10.1128/JVI.78.19.10724-10737.2004. ISSN   0022-538X. PMC   516390 . PMID   15367639.
  10. 1 2 3 4 5 Huarte, Nerea; Araujo, Aitziber; Arranz, Rocio; Lorizate, Maier; Quendler, Heribert; Kunert, Renate; Valpuesta, José M.; Nieva, José L. (2012-12-21). "Recognition of Membrane-Bound Fusion-Peptide/MPER Complexes by the HIV-1 Neutralizing 2F5 Antibody: Implications for Anti-2F5 Immunogenicity". PLOS ONE. 7 (12): e52740. Bibcode:2012PLoSO...752740H. doi: 10.1371/journal.pone.0052740 . ISSN   1932-6203. PMC   3528738 . PMID   23285173.
  11. ↑ Alam, S. Munir; McAdams, Mildred; Boren, David; Rak, Michael; Scearce, Richard M.; Gao, Feng; Camacho, Zenaido T.; Gewirth, Daniel; Kelsoe, Garnett (2007-04-01). "The Role of Antibody Polyspecificity and Lipid Reactivity in Binding of Broadly Neutralizing Anti-HIV-1 Envelope Human Monoclonal Antibodies 2F5 and 4E10 to Glycoprotein 41 Membrane Proximal Envelope Epitopes". The Journal of Immunology. 178 (7): 4424–4435. doi:10.4049/jimmunol.178.7.4424. ISSN   0022-1767. PMC   2262928 . PMID   17372000.
  12. 1 2 Stiegler, G. (2003-04-01). "Therapeutic potential of neutralizing antibodies in the treatment of HIV-1 infection". Journal of Antimicrobial Chemotherapy. 51 (4): 757–759. doi: 10.1093/jac/dkg172 . ISSN   0305-7453. PMID   12654737.
  13. ↑ Hessell, Ann J.; Rakasz, Eva G.; Tehrani, David M.; Huber, Michael; Weisgrau, Kimberly L.; Landucci, Gary; Forthal, Donald N.; Koff, Wayne C.; Poignard, Pascal (2010-02-01). "Broadly neutralizing monoclonal antibodies 2F5 and 4E10 directed against the human immunodeficiency virus type 1 gp41 membrane-proximal external region protect against mucosal challenge by simian-human immunodeficiency virus SHIVBa-L". Journal of Virology. 84 (3): 1302–1313. doi:10.1128/JVI.01272-09. ISSN   1098-5514. PMC   2812338 . PMID   19906907.
  14. ↑ Bryson, Steve; Julien, Jean-Philippe; Hynes, Rosemary C.; Pai, Emil F. (2017-02-23). "Crystallographic Definition of the Epitope Promiscuity of the Broadly Neutralizing Anti-Human Immunodeficiency Virus Type 1 Antibody 2F5: Vaccine Design Implications". Journal of Virology. 83 (22): 11862–11875. doi:10.1128/JVI.01604-09. ISSN   0022-538X. PMC   2772703 . PMID   19740978.
  15. ↑ Tudor, Daniela; Drillet, Anne-Sophie; Schwartz-Cornil, Isabelle; Shen, Ruizhong; Smith, Phillip D; Bomsel, Morgane (2010-05-11). "The immunoglobulin CH1 constant region modulates antigen binding affinity and functional activities of the broadly neutralizing 2F5 HIV specific antibody". Retrovirology. 7 (Suppl 1): P23. doi:10.1186/1742-4690-7-S1-P23. ISSN   1742-4690. PMC   3315950 .
  16. ↑ Tudor, Daniela; Yu, Huifeng; Maupetit, Julien; Drillet, Anne-Sophie; Bouceba, Tahar; Schwartz-Cornil, Isabelle; Lopalco, Lucia; Tuffery, Pierre; Bomsel, Morgane (2012-07-31). "Isotype modulates epitope specificity, affinity, and antiviral activities of anti–HIV-1 human broadly neutralizing 2F5 antibody". Proceedings of the National Academy of Sciences. 109 (31): 12680–12685. doi: 10.1073/pnas.1200024109 . ISSN   0027-8424. PMC   3412007 . PMID   22723360.
  17. ↑ Crespillo, Sara; Casares, Salvador; Mateo, Pedro L.; Conejero-Lara, Francisco (2014-01-10). "Thermodynamic Analysis of the Binding of 2F5 (Fab and Immunoglobulin G Forms) to Its gp41 Epitope Reveals a Strong Influence of the Immunoglobulin Fc Region on Affinity". Journal of Biological Chemistry. 289 (2): 594–599. doi: 10.1074/jbc.C113.524439 . ISSN   0021-9258. PMC   3887187 . PMID   24302742.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.